CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Ocugen, Inc. - OCGN CFD

1.44
0.7%
0.05
Low: 1.38
High: 1.47
Market Trading Hours* (UTC) Open now
Closes on Thursday at 01:00

Mon: 09:10 - 00:00

Tue - Thu: 00:00 - 01:00 09:10 - 00:00

Fri: 00:00 - 01:00 09:10 - 22:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0064 %
Charges from borrowed part ($-0.26)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0064%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0064 %
Charges from borrowed part ($-0.26)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0059%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 1.43
Open* 1.43
1-Year Change* -77.59%
Day's Range* 1.38 - 1.38
52 wk Range 1.48-7.55
Average Volume (10 days) 4.8687
Average Volume (3 months) 106.018
Market Cap 339.275
P/E Ratio N/A
Shares Outstanding 218887000
Revenue N/A
EPS -0.35219
Dividend (Yield %) N/A
Beta 4.03869
Next Earnings Date Feb 23, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Nov 30, 2022 1.42 0.00 0.00% 1.42 1.43 1.40
Nov 29, 2022 1.43 0.00 0.00% 1.43 1.47 1.40
Nov 28, 2022 1.43 -0.04 -2.72% 1.47 1.51 1.42
Nov 25, 2022 1.48 -0.05 -3.27% 1.53 1.53 1.48
Nov 23, 2022 1.50 0.00 0.00% 1.50 1.56 1.48
Nov 22, 2022 1.51 -0.02 -1.31% 1.53 1.57 1.48
Nov 21, 2022 1.54 -0.03 -1.91% 1.57 1.59 1.51
Nov 18, 2022 1.57 0.03 1.95% 1.54 1.63 1.54
Nov 17, 2022 1.55 -0.07 -4.32% 1.62 1.63 1.54
Nov 16, 2022 1.62 -0.03 -1.82% 1.65 1.72 1.60
Nov 15, 2022 1.66 -0.03 -1.78% 1.69 1.76 1.65
Nov 14, 2022 1.69 -0.06 -3.43% 1.75 1.77 1.66
Nov 11, 2022 1.74 0.11 6.75% 1.63 1.80 1.61
Nov 10, 2022 1.64 0.10 6.49% 1.54 1.70 1.45
Nov 9, 2022 1.45 -0.13 -8.23% 1.58 1.60 1.44
Nov 8, 2022 1.59 0.09 6.00% 1.50 1.66 1.49
Nov 7, 2022 1.51 -0.05 -3.21% 1.56 1.61 1.48
Nov 4, 2022 1.58 0.04 2.60% 1.54 1.62 1.54
Nov 3, 2022 1.54 -0.04 -2.53% 1.58 1.64 1.53
Nov 2, 2022 1.59 -0.08 -4.79% 1.67 1.70 1.56

Ocugen, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 0 0 0 0 0.04262 0
Revenue 0 0 0 0.04262 0
Total Operating Expense 30.307 24.95 28.568 14.5038 21.3273 57.628
Selling/General/Admin. Expenses, Total 8.53 9.384 10.204 6.0771 7.97405 22.92
Research & Development 21.577 15.566 15.634 8.08552 13.3533 35.108
Unusual Expense (Income) 0.2 0 2.73 0.34114 0 -0.4
Operating Income -30.307 -24.95 -28.568 -14.5038 -21.2847 -57.628
Interest Income (Expense), Net Non-Operating 14.347 -1.348 20.031 -4.95401 -0.71989 -0.079
Other, Net -0.248 -0.116 -0.106 -0.78487 0.18266 -0.71
Net Income Before Taxes -16.208 -26.414 -8.643 -20.2426 -21.822 -58.417
Net Income After Taxes -16.208 -26.414 -8.643 -20.2426 -21.822 -58.365
Net Income Before Extra. Items -16.208 -26.414 -8.643 -20.2426 -21.822 -58.365
Net Income -16.208 -26.414 -8.643 -20.2426 -21.822 -58.365
Total Adjustments to Net Income 2.345 3.915 0.121 -12.5463 0
Income Available to Common Excl. Extra. Items -13.863 -22.499 -8.522 -20.2426 -34.3683 -58.365
Income Available to Common Incl. Extra. Items -13.863 -22.499 -8.522 -20.2426 -34.3683 -58.365
Diluted Net Income -13.863 -22.499 -8.522 -20.2426 -34.3683 -58.365
Diluted Weighted Average Shares 0.23766 0.37791 0.60676 13.8938 112.236 195.013
Diluted EPS Excluding Extraordinary Items -58.3304 -59.536 -14.045 -1.45695 -0.30621 -0.29929
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -57.4889 -59.536 -9.54575 -1.4324 -0.30621 -0.30062
Total Extraordinary Items 0
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 0 0 0 0 0
Total Operating Expense 7.057 25.61 10.389 14.572 18.034
Selling/General/Admin. Expenses, Total 4.185 6.757 4.508 7.47 10.119
Research & Development 2.872 18.853 6.281 7.102 7.915
Operating Income -7.057 -25.61 -10.389 -14.572 -18.034
Interest Income (Expense), Net Non-Operating -0.02 -0.01 -0.014 -0.035
Net Income Before Taxes -7.077 -25.952 -10.807 -14.581 -18.019
Net Income After Taxes -7.077 -25.952 -10.755 -14.581 -18.019
Net Income Before Extra. Items -7.077 -25.952 -10.755 -14.581 -18.019
Net Income -7.077 -25.952 -10.755 -14.581 -18.019
Income Available to Common Excl. Extra. Items -7.077 -25.952 -10.755 -14.581 -18.019
Income Available to Common Incl. Extra. Items -7.077 -25.952 -10.755 -14.581 -18.019
Diluted Net Income -7.077 -25.952 -10.755 -14.581 -18.019
Diluted Weighted Average Shares 186.298 195.572 198.791 199.254 205.693
Diluted EPS Excluding Extraordinary Items -0.03799 -0.1327 -0.0541 -0.07318 -0.0876
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.03799 -0.1327 -0.05541 -0.07318 -0.0876
Revenue 0 0 0
Other, Net -0.332 -0.404 0.026 0.015
Total Adjustments to Net Income 0 0 0
Unusual Expense (Income) -0.4 0
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 32.081 8.175 16.4 15.7662 25.8777 102.646
Cash and Short Term Investments 31.908 7.981 15.542 7.44405 24.0393 94.958
Cash & Equivalents 31.908 7.081 15.542 7.44405 24.0393 94.958
Prepaid Expenses 0.173 0.194 0.686 1.32217 1.83836 2.7
Total Assets 36.078 11.035 17.428 16.8074 27.3764 105.761
Property/Plant/Equipment, Total - Net 3.86 2.723 0.141 0.22246 1.06662 2.751
Intangibles, Net 0
Other Long Term Assets, Total 0.137 0.137 0.887 0.81876 0.43205 0.364
Total Current Liabilities 5.171 3.805 2.873 4.54396 3.61355 7
Accounts Payable 1.948 0.776 1.59 1.89561 0.39503 2.312
Accrued Expenses 2.097 2.705 1 2.44236 2.97464 4.688
Notes Payable/Short Term Debt 0 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.583 0.178 0 0 0.23412 0
Other Current Liabilities, Total 0.543 0.146 0.283 0.20599 0.00976
Total Liabilities 22.511 22.303 17.886 5.78904 5.82591 9.943
Total Long Term Debt 0.178 0 0 1.07212 1.82304 1.712
Long Term Debt 0.178 0 1.07212 1.82304 1.712
Other Liabilities, Total 17.162 18.498 15.013 0.17295 0.38932 1.231
Total Equity 13.567 -11.268 -0.458 11.0184 21.5504 95.818
Common Stock 0.159 0.159 0.513 0.52747 1.84133 1.995
Additional Paid-In Capital 195.181 196.76 215.859 62.0186 93.0587 225.537
Retained Earnings (Accumulated Deficit) -181.773 -208.187 -216.83 -51.4798 -73.3018 -131.667
Total Liabilities & Shareholders’ Equity 36.078 11.035 17.428 16.8074 27.3764 105.761
Total Common Shares Outstanding 0.3442 0.4096 1.03376 52.6252 184.012 199.381
Short Term Investments 0.9 0
Redeemable Preferred Stock 0 0 0 0.001
Other Equity, Total 0 0
Other Current Assets, Total 0.172 7 0 4.988
Property/Plant/Equipment, Total - Gross 10.427 1.29231 3.125
Accumulated Depreciation, Total -10.286 -0.2257 -0.374
Treasury Stock - Common -0.04786 -0.04786 -0.048
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 51.356 121.626 113.45 102.646 138.027
Cash and Short Term Investments 44.792 115.642 107.349 94.958 129.771
Cash & Equivalents 44.792 115.642 107.349 94.958 129.771
Prepaid Expenses 1.576 0.996 1.113 2.7 8.256
Other Current Assets, Total 4.988 4.988 4.988 4.988
Total Assets 53.847 124.251 116.312 105.761 141.727
Property/Plant/Equipment, Total - Net 0.762 0.944 1.052 2.751 3.345
Property/Plant/Equipment, Total - Gross 0.988 1.219 1.386 3.125 3.786
Accumulated Depreciation, Total -0.226 -0.275 -0.334 -0.374 -0.441
Other Long Term Assets, Total 1.729 1.681 1.81 0.364 0.355
Total Current Liabilities 4.281 4.84 6.229 7 7.687
Accounts Payable 1.04 0.802 2.095 2.312 3.896
Accrued Expenses 2.867 4.038 4.134 4.688 3.791
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.374 0 0 0
Total Liabilities 7.358 7.842 9.202 9.943 10.598
Total Long Term Debt 1.702 1.674 1.693 1.712 1.731
Long Term Debt 1.702 1.674 1.693 1.712 1.731
Other Liabilities, Total 1.375 1.328 1.28 1.231 1.18
Total Equity 46.489 116.409 107.11 95.818 131.129
Common Stock 1.883 1.988 1.99 1.995 2.158
Additional Paid-In Capital 125.032 220.799 222.253 225.537 278.704
Retained Earnings (Accumulated Deficit) -80.379 -106.331 -117.086 -131.667 -149.686
Treasury Stock - Common -0.048 -0.048 -0.048 -0.048 -0.048
Other Equity, Total 0.001
Total Liabilities & Shareholders’ Equity 53.847 124.251 116.312 105.761 141.727
Total Common Shares Outstanding 188.156 198.695 198.928 199.381 215.631
Redeemable Preferred Stock 0.001 0.001 0.001 0.001
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -16.208 -26.414 -8.643 -20.2426 -21.822 -58.365
Cash From Operating Activities -25.736 -23.02 -15.777 -16.8933 -14.7087 -47.941
Cash From Operating Activities 1.673 1.534 0.45 0.06061 0.10211 0.229
Non-Cash Items -13.192 2.566 -14.779 6.40129 8.2213 7.757
Cash Taxes Paid 0.257 0.197 0.105 0.052
Cash Interest Paid 0.066 0.03 0.001
Changes in Working Capital 1.991 -0.706 7.195 -3.11255 -1.21018 2.438
Cash From Investing Activities -0.32 -1.23 -1.113 -2.35672 -0.30683 -1.816
Capital Expenditures -0.32 -0.276 -2.013 -0.02945 -0.30683 -1.066
Cash From Financing Activities 27.049 -0.577 25.351 25.0665 31.611 120.676
Financing Cash Flow Items -0.583 -0.583 -0.178 -0.17293 -1.48355 -8.525
Issuance (Retirement) of Stock, Net 27.632 0.006 25.529 23.7294 37.822 129.211
Net Change in Cash 0.993 -24.827 8.461 5.81646 16.5955 70.919
Other Investing Cash Flow Items, Total -0.954 0.9 -2.32727 0 -0.75
Issuance (Retirement) of Debt, Net 1.51 -4.72744 -0.01
Foreign Exchange Effects 0
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -7.077 -33.029 -43.784 -58.365 -18.019
Cash From Operating Activities -5.283 -27.084 -35.137 -47.941 -15.066
Cash From Operating Activities 0.044 0.093 0.151 0.229 0.076
Non-Cash Items 0.921 3.434 4.869 7.757 3.497
Changes in Working Capital 0.829 2.418 3.627 2.438 -0.62
Cash From Investing Activities -0.261 -1.274 -1.624 -1.816 -0.223
Capital Expenditures -0.261 -0.524 -0.874 -1.066 -0.223
Cash From Financing Activities 26.297 119.961 120.071 120.676 50.102
Financing Cash Flow Items -1.822 -8.525 -8.525 -8.525 -0.075
Issuance (Retirement) of Stock, Net 28.125 128.496 128.606 129.211 50.177
Issuance (Retirement) of Debt, Net -0.006 -0.01 -0.01 -0.01 0
Net Change in Cash 20.753 91.603 83.31 70.919 34.813
Other Investing Cash Flow Items, Total -0.75 -0.75 -0.75
Cash Taxes Paid 0.052 0.052

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
475000+

Traders

71000+

Active clients monthly

$51000000+

Monthly investing volume

$30000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Ocugen, Inc. Company profile

Ocugen (OCGN) is a biopharmaceutical company focusing on discovering, developing, and commercialising gene therapies to cure blindness illnesses and creating a Covid-19 vaccine. 

Founded in 2006, Ocugen became a public company in 2014. The company’s shares are traded on the Nasdaq under the symbol OCGN.

Projects in the pipeline are Covid-19 vaccines, a Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. 

For the Covid-19 vaccine, the company, in collaboration Bharat Biotech, was developing, manufacturing and commercialising COVAXIN for the prevention of the disease for US and Canada markets. COVAXIN is a whole-virion inactivated Covid-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus.

The Modifier Gene Therapy Platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). The technology is licensed from the Schepens Eye Research Institute of Massachusetts Eye and Ear (Harvard Medical School).

The company is developing OCU200, a biologic product candidate for the treatment of severe vision-threatening diseases such as diabetic macular edema (DME), diabetic retinopathy (DR), and wet age-related macular degeneration (Wet-AMD). 

Patients affected by these diseases have common symptoms, such as blurry vision and increasing visual loss as the condition develops.

Another technology in the pipeline is OCU400, the company’s first product candidate developed with its Modifier Gene Therapy Platform.

Ocugen is headquartered in Malvern, Pennsylvania.

Industry: Biotechnology & Medical Research (NEC)

11 Great Valley Parkway
MALVERN
PENNSYLVANIA 19355
US

Income Statement

People also watch

Natural Gas

6.88 Price
-4.930% 1D Chg, %
Long position overnight fee 0.0593%
Short position overnight fee -0.0879%
Overnight fee time 22:00 (UTC)
Spread 0.005

BTC/USD

16,917.60 Price
+2.400% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 66.00

Oil - Crude

80.32 Price
+1.660% 1D Chg, %
Long position overnight fee -0.0106%
Short position overnight fee -0.0029%
Overnight fee time 22:00 (UTC)
Spread 0.03

XRP/USD

0.40 Price
+0.550% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 0.00320

Still looking for a broker you can trust?

Join the 475.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading